Frontiers in Public Health (Jan 2023)

Racial inequality in COVID-treatment and in-hospital length of stay in the US over time

  • Benjamin M. Althouse,
  • Benjamin M. Althouse,
  • Benjamin M. Althouse,
  • Charlotte Baker,
  • Peter D. Smits,
  • Samuel Gratzl,
  • Ryan H. Lee,
  • Brianna M. Goodwin Cartwright,
  • Michael Simonov,
  • Michael Simonov,
  • Michael D. Wang,
  • Nicholas L. Stucky

DOI
https://doi.org/10.3389/fpubh.2022.1074775
Journal volume & issue
Vol. 10

Abstract

Read online

IntroductionDemonstrated health inequalities persist in the United States. SARS-CoV-2 (COVID) has been no exception, with access to treatment and hospitalization differing across race or ethnic groups. Here, we aim to assess differences in treatment with remdesivir and hospital length of stay across the four waves of the pandemic.Materials and methodsUsing a subset of the Truveta data, we examine the odds ratio (OR) of in-hospital remdesivir treatment and risk ratio (RR) of in-hospital length of stay between Black or African American (Black) to White patients. We adjusted for confounding factors, such as age, sex, and comorbidity status.ResultsThere were statistically significant lower rates of remdesivir treatment and longer in-hospital length of stay comparing Black patients to White patients early in the pandemic (OR for treatment: 0.88, 95% confidence interval [CI]: 0.80, 0.96; RR for length of stay: 1.17, CI: 1.06, 1.21). Rates became close to parity between groups as the pandemic progressed.ConclusionWhile inpatient remdesivir treatment rates increased and length of stay decreased over the beginning course of the pandemic, there are still inequalities in patient care.

Keywords